Search

Zentalis Pharmaceuticals Inc

Geschlossen

4.26 3.65

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.04

Max

4.3

Schlüsselkennzahlen

By Trading Economics

Einkommen

-42M

-78M

EPS

-0.59

Angestellte

106

EBITDA

-42M

-77M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+88.56% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-34M

297M

Vorheriger Eröffnungskurs

0.61

Vorheriger Schlusskurs

4.26

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Aug. 2026, 23:56 UTC

Zions Bancorporation shares are higher in after-market hours, continuing gains amid broader market dynamics influenced by recent U.S. Consumer Price Index data.

12. Aug. 2026, 23:56 UTC

News

Allegro Microsystems shares rose in after-market trading following Benchmark's initiation of coverage with a Buy rating. The stock closed at $42.52.

12. Aug. 2026, 23:56 UTC

JinkoSolar shares are higher in after-market trading, reflecting a modest uptick since Wednesday's close amid U.S. Consumer Price Index data release.

12. Aug. 2026, 23:56 UTC

Yum Brands Inc. shares are higher in after-market trading, reflecting routine performance amid broader market dynamics following the release of U.S. Consumer Price Index data.

12. Aug. 2026, 23:56 UTC

Griffon Corp shares are higher in after-market hours, supported by U.S. Consumer Price Index data easing concerns over Federal Reserve interest rate hikes.

12. Aug. 2026, 23:56 UTC

Social Media
News

STAAR Surgical shares are lower in after-market hours following an EPS miss, despite reporting second-quarter net sales of $93.5 million, a 111% increase.

12. Aug. 2026, 23:56 UTC

MasTec Inc shares are higher in after-market hours, recovering from an earlier dip. The movement aligns with broader market dynamics following U.S. CPI data.

12. Aug. 2026, 23:56 UTC

Molina Healthcare Inc shares are higher in after-market hours, following the release of U.S. Consumer Price Index data that met expectations.

12. Aug. 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

12. Aug. 2026, 23:56 UTC

ETF Constituents

Vanguard FTSE Emerging Markets ETF shows modest after-market gains, supported by Taiwan Semiconductor and Pinduoduo. The ETF is near its one-month range's upper end.

12. Aug. 2026, 23:56 UTC

Ares Capital Corp shares are lower in after-market hours, continuing a three-session decline amid market volatility following U.S. Consumer Price Index data release.

12. Aug. 2026, 23:56 UTC

DaVita Inc shares are lower in after-market trading following a session peak. The stock remains under pressure, trading below its 20-day moving average.

12. Aug. 2026, 23:56 UTC

ETF Constituents
Correlated Moves

VanEck Gold Miners ETF declines in after-market trading, impacted by top holdings including Pan American Silver's drop and slight decreases in silver prices.

12. Aug. 2026, 23:56 UTC

Chevron Corp shares gained during after-market hours following the release of U.S. Consumer Price Index data, which eased concerns about Federal Reserve interest rate hikes.

12. Aug. 2026, 23:56 UTC

Social Media

Snowflake Inc. shares advanced in after-market trading, buoyed by U.S. CPI data and positive sentiment in tech sector discussions.

12. Aug. 2026, 23:56 UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

12. Aug. 2026, 23:56 UTC

Gogo Inc. shares are higher in after-market trading, following the release of U.S. Consumer Price Index data that met expectations and eased rate hike concerns.

12. Aug. 2026, 23:56 UTC

Comcast shares declined in after-market trading, following the release of U.S. Consumer Price Index data. The stock remains above its 20-day moving average.

12. Aug. 2026, 23:56 UTC

elf Beauty Inc. shares are lower in after-market trading, continuing a four-session decline. The stock remains above its 20-day moving average.

12. Aug. 2026, 23:54 UTC

Ambarella Inc. shares remained roughly flat in after-market hours, with no specific news identified. The stock is positioned above its 20-day moving average.

12. Aug. 2026, 23:52 UTC

UK House Price Balance Shows Slight Improvement at -0.3%, Indicating Ongoing Market Challenges Despite Optimism for Future Stabilization

12. Aug. 2026, 23:52 UTC

RBA Holds Cash Rate at 4.35% Amid Inflation Concerns; Assistant Governor Kent's Upcoming Speech Sparks Market Speculation

12. Aug. 2026, 23:52 UTC

Canada's housing starts data set for release on August 18, following June's decline and amid government initiatives to boost affordable home construction.

12. Aug. 2026, 23:52 UTC

Australia's Consumer Confidence Report Set for August 18 Amidst Cautious Market Sentiment and Economic Volatility.

12. Aug. 2026, 23:52 UTC

Australia's Consumer Confidence Index release on August 18, 2026, faces cautious market expectations amid mixed economic signals and ongoing geopolitical tensions.

12. Aug. 2026, 23:52 UTC

Brazil's Industrial Entrepreneur Confidence Index Expected to Remain Low Amid Economic Uncertainty, Anticipating Continued Pessimism Ahead of August 13 Release.

12. Aug. 2026, 23:52 UTC

Australia's Investment Lending Data Release on August 14 Expected to Impact Housing Market Insights Amid Cautious Sentiment.

12. Aug. 2026, 23:52 UTC

Japan's Upcoming Export Data Release on August 19, 2026, Expected to Reflect Trends in High-Tech Products Amid Global Economic Uncertainties.

12. Aug. 2026, 23:52 UTC

Japan's Upcoming Balance of Trade Data Expected to Show Continued Deficits Amid Rising Imports and Geopolitical Tensions

12. Aug. 2026, 23:52 UTC

JD.Com Inc. shares are lower in after-hours trading, reversing from an early gain amid broader market trends influenced by recent inflation data.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

88.56% Vorteil

12-Monats-Prognose

Durchschnitt 7.75 USD  88.56%

Hoch 11 USD

Tief 4 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

3

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat